Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 9
2004 9
2005 9
2006 9
2007 11
2008 15
2009 11
2010 16
2011 12
2012 6
2013 10
2014 7
2015 7
2016 8
2017 1
2018 7
2019 4
2020 3
2021 4
2022 3
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

155 results

Results by year

Filters applied: . Clear all
Page 1
Identification of actionable targets for breast cancer intervention using a diversity outbred mouse model.
Jacob JB, Wei KC, Bepler G, Reyes JD, Cani A, Polin L, White K, Kim S, Viola N, McGrath J, Guastella A, Yin C, Mi QS, Kidder BL, Wagner KU, Ratner S, Phillips V, Xiu J, Parajuli P, Wei WZ. Jacob JB, et al. Among authors: bepler g. iScience. 2023 Mar 2;26(4):106320. doi: 10.1016/j.isci.2023.106320. eCollection 2023 Apr 21. iScience. 2023. PMID: 36968078 Free PMC article.
ATR inhibition overcomes platinum tolerance associated with ERCC1- and p53-deficiency by inducing replication catastrophe.
Heyza JR, Ekinci E, Lindquist J, Lei W, Yunker C, Vinothkumar V, Rowbotham R, Polin L, Snider NG, Van Buren E, Watza D, Back JB, Chen W, Mamdani H, Schwartz AG, Turchi JJ, Bepler G, Patrick SM. Heyza JR, et al. Among authors: bepler g. NAR Cancer. 2023 Jan 11;5(1):zcac045. doi: 10.1093/narcan/zcac045. eCollection 2023 Mar. NAR Cancer. 2023. PMID: 36644397 Free PMC article.
A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib.
Camidge DR, Moran T, Demedts I, Grosch H, Mileham K, Molina J, Juan-Vidal O, Bepler G, Goldman JW, Park K, Wallin J, Wijayawardana SR, Wang XA, Wacheck V, Smit E. Camidge DR, et al. Among authors: bepler g. Clin Lung Cancer. 2022 Jun;23(4):300-310. doi: 10.1016/j.cllc.2022.03.003. Epub 2022 Mar 17. Clin Lung Cancer. 2022. PMID: 35400584 Clinical Trial.
The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer.
Nagasaka M, Singh V, Baca Y, Sukari A, Kim C, Mamdani H, Spira AI, Uprety D, Bepler G, Kim ES, Raez LE, Pai SG, Ikpeazu C, Oberley M, Feldman R, Xiu J, Korn WM, Wozniak AJ, Borghaei H, Liu SV. Nagasaka M, et al. Among authors: bepler g. Clin Lung Cancer. 2022 Jan;23(1):52-59. doi: 10.1016/j.cllc.2021.08.012. Epub 2021 Oct 18. Clin Lung Cancer. 2022. PMID: 34801409 Free article.
Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC).
Nagasaka M, Asad MFB, Al Hallak MN, Uddin MH, Sukari A, Baca Y, Xiu J, Magee D, Mamdani H, Uprety D, Kim C, Xia B, Liu SV, Nieva JJ, Lopes G, Bepler G, Borghaei H, Demeure MJ, Raez LE, Ma PC, Puri S, Korn WM, Azmi AS. Nagasaka M, et al. Among authors: bepler g. Lung Cancer. 2021 Oct;160:92-98. doi: 10.1016/j.lungcan.2021.08.010. Epub 2021 Aug 27. Lung Cancer. 2021. PMID: 34482103 Free PMC article.
155 results